Canada: Canada’s Natural Health Products Regime – An Update

Last Updated: June 11 2007
Article by Tanya Baytor

This article first appeared in Update, Issue 3, May/June 2007.
Reprinted with permission of the Food and Drug Law Institute (FDLI) © 2007.

Canada’s Natural Health Products (NHPs) regime was implemented with the promulgation of the Natural Health Products Regulations (Regulations) on January 1, 2004. NHPs are Canada’s equivalent to dietary supplements in the United States, and include vitamins, minerals and herbs.

NHPs are considered a subset of drugs and were an addition to the scheme under the Canadian Food and Drugs Act, which governs food, drugs, medical devices and cosmetics. Previously, NHPs were not recognized under this legislation and were sold with the tacit approval of Health Canada. The intent behind the regime is to ensure that NHPs available to Canadian consumers were subjected to regulatory scrutiny and proven to be safe. The Natural Health Products Directorate (Directorate) maintains, "Our role is to ensure that Canadians have ready access to natural health products that are safe, effective and of high quality while respecting freedom of choice and philosophical and cultural diversity."

Under the Regulations, NHPs are materials, extracts or isolates of plants, algae, bacteria, fungus or animals; natural or synthetic amino acids, essential fatty acids or certain vitamins; minerals; probiotics; homeopathic or traditional medicines that are manufactured, sold or represented for use in the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state or its symptoms, or for restoring, modifying or correcting organic functions in humans.

The Regulations require that all NHPs be approved by the Directorate in order to receive an NHP license and an NHP number (NPN). No NHP may be sold without an NHP license. The holder of that license has a continuing obligation to monitor all adverse reactions with respect to the NHP, to document these reactions in an annual summary report, and to report to the Ministry of Health all serious adverse reactions in Canada or serious unexpected adverse reactions anywhere in the world. The holder of the NHP license is obligated to maintain records related to the ingredients contained in each lot or batch of the NHP and sufficient information to enable the recall of every lot or batch made available for sale.

Canadian importers must have a site license and they have the onus to provide evidence that imported products come from sites that meet the Canadian Good Manufacturing Practices or equivalent standards. The Canadian importer is responsible for submitting a Quality Assurance Report for each site. Site licenses are issued only to Canadian sites (none are issued to foreign sites). Foreign manufacturers will be covered under the Canadian importer’s site license. Site license holders are required to comply with the specifications submitted in an application for an NHP license, as well as requirements related to recordkeeping, recall reporting, personnel, premises, sanitation programs, quality assurance, stability, operations, sterile products, ophthalmic-use products and lot or batch samples.

A Backlog of Applications

The use of NHPs is steadily on the rise. In 2005, Health Canada reported that due to the ever-increasing interest in the potential health benefits of these products, the proportion of NHP users was 71 percent of the Canadian population, with about 77 percent of Canadians believing that NHPs can be used to maintain or support health.

The vast number of NHPs to be approved is posing a challenge to the relatively young Directorate, which must process thousands of product and site license applications.

In April 2006, the Directorate reported a backlog of over 10,000 product applications and notified industry stakeholders that it would be introducing backlog-reduction measures. It said that it would process only complete product license applications and refuse those deemed incomplete. The Directorate began issuing Notices of Refusal and about 1,900 were removed from the processing queues. The backlog of unprocessed site license applications was 330 in October 2006.

The Directorate makes it clear that manufacturers should not market their products without a valid market authorization (NHP license). A submission number is only proof of the receipt of a complete Product License Application and is not an authorization for sale. However, under the Directorate’s existing policy, Health Canada will focus its compliance efforts on NHPs that have not been issued a submission number or those that have been identified as posing an unacceptable health risk. The product-specific submission number issued by the Directorate is further required to facilitate border entry of imported products. If such information is not provided, products will be detained at Customs, and inspectors will recommend refusal of entry.

As a result, many NHPs are currently on the market in Canada with pending NHP license applications. For manufacturers and importers of NHPs in Canada, the current state of the regulatory process has resulted in a legal quagmire.

Risk-Based Enforcement

Manufacturers of products that were licensed as drugs before the Regulations were enacted have until December 31, 2009, to obtain NHP licenses. Products new to the market after January 1, 2004, require pre-approval before sale.

In the Natural Health Products Compliance Guide, Health Canada outlines its risk-based approach to the enforcement of the NHP regulations, and states that "all NHPs identified as posing an unacceptable risk to the health of Canadians will be removed from sale." An NHP is considered to be noncompliant if it has no valid market authorization (an NHP license) or has such authorization but is otherwise non-compliant with the Regulations. Although any NHP posing a health risk will be subject to enforcement measures, Health Canada has created a category-based compliance strategy. This strategy complements, but is superseded by, the riskbased approach. Compliance deadlines for each product class are staggered from June 1, 2004, to June 1, 2008.

Health Canada considers as its No. 1 priority concern NHPs whose substances and formulations lack any, or adequate, information on their safe use; such lack indicates that their safety and efficacy for medicinal purposes have not been established. Its No. 2 priority comprises isolates, amino acids, fatty acids, concentrated volatile (essential) oils indicated for internal use. Its No. 3 category of prioritization includes algae, bacterial, probiotic, fungal and non-human animal materials because although they generally present less risk than selective concentrates, problems may arise from the application of these products as a result of improper concentration, inadequate ingredient identification or lack of adherence to Good Manufacturing Practices. Its No. 4 priority covers plant, plant materials, extracts prepared by traditional methods and volatile (essential) oils other than those that are concentrated and indicated for internal use because they present less risk than extracts or isolates. Its No. 5 priority includes vitamins and minerals, which are mostly well-known with regard to safe conditions of use as dietary supplements. And its No. 6 and last category of prioritization comprises homeopathic medicines, which are considered to present low risk because most do not contain a material dose of a medicinal ingredient, and standards for product quality are well-established in pharmacopoeia.

Industry Reaction

For many companies based in Canada and companies based in the United States with products on the Canadian market, the Regulations represented a significant shift in the industry, creating a substantially increased regulatory burden and requiring several changes in company practices. The lengthy license-application processing times and Health Canada’s risk-based approach to compliance creates further challenges for companies seeking to comply with the law while maintaining their presence in the NHP arena in Canada.

For some smaller companies in the industry, the process of attaining a product license is too lengthy and expensive; they have decided, therefore, to ignore the Canadian market altogether. Other large companies have decided to embrace the Regulations and use them to their benefit by gaining market advantage over competitors. Commentators noted, "A perceived market advantage is gained because a company that obtains [an] NPN is able to sell the product with a new health claim before other companies." The NHP license is regarded as beneficial because consumers are likely to prefer a product with an NPN over a product without one. The NHP regime is thus viewed as providing a strategic advantage to larger companies because by complying with the Regulations, a company can maintain its position in the NHP industry and "squeeze others out of the market."

The regulatory landscape is, however, fraught with uncertainty for companies whose NHP license applications are pending. Depending on the type of NHP, the licensing process can take years, by which time a company may have lost its position in the market. Given Health Canada’s risk-based approach to enforcement of the Regulations, many companies decide to enter the Canadian market without an NHP license. Prudent companies attempt to comply as closely as possible with the standards adopted by similar products for which the Directorate has already issued a license. Once the product license application is in the queue and a submission number has been issued, the manufacturer proceeds to market the product in Canada. Some companies push the envelope with respect to new products that may not comply with the standards imposed by the Regulations but face no penalties; this is frustrating to others in the industry that take the high road by adhering to the requirements under the new regime (to the extent they can).

As the Directorate works its way through its seemingly endless backlog of product and site license applications and as enforcement policies become less flexible, it will be interesting to observe how the NHP industry reaction develops and shapes the marketplace for NHPs in Canada. Only then will it be possible to conduct a meaningful assessment of the NHP regime in Canada.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions